Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + cyclophosphamide + doxorubicin + medroxyprogesterone acetate
- Development stage
- Unknown
- Lead developer
- Baxter
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral, Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of three cytotoxic agents (5-fluorouracil, cyclophosphamide, and doxorubicin/adriamycin) plus a hormonal therapy agent (medroxyprogesterone acetate). The regimen has been studied primarily for the treatment of metastatic breast cancer. In clinical trials, medroxyprogesterone acetate was administered at high doses (500 mg/day intramuscularly for 21 days, followed by either 500 mg/week intramuscularly or 300 mg/day orally) in combination with the standard FAC regimen.
- Other names
- FAC plus high-dose medroxyprogesterone acetate
02
Targets
DNAPR (Progesterone receptor)TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on 5-fluorouracil + cyclophosphamide + doxorubicin + medroxyprogesterone acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + cyclophosphamide + doxorubicin + medroxyprogesterone acetate.